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Background
Heart failure (HF) is a significant cause of mortality in children and therefore there is interest in understanding the
optimal way to support these children with Ventricular
Assist Devices (VAD) to improve outcomes. VAD therapy
is now regarded as an important treatment option in pediatric HF. The 2019 International Society for Heart and Lung
Transplantation (ISHLT) registry report shows that there is
an increasing trend towards using VADs as a bridge to
transplant (BTT) with currently over one-third of patients
transplanted being bridged with a VAD.1
The immediate aim of VAD therapy is to provide hemodynamic stability for a failing circulation unresponsive to
medical therapy. The VAD should be implanted before the
development of severe end-organ dysfunction in order to
optimize clinical outcomes. The goal is to improve tissue and
organ perfusion, improve quality of life (QoL) and improve
waitlist survival. Importantly, VAD therapy may not only
lead to patient stability but may also afford the opportunity
for patient rehabilitation prior to heart transplantation (HT).
Despite the increase in VAD use within pediatrics over
the last decade, the majority of centers implant less than 10
VADs in children per year.2 Thus, local data is limited for
analysis of outcomes and therefore multi-center collaboration and consensus is essential in understanding this complex and dynamic field.
ISHLT has recognized the importance of a consensus
statement on the selection and management of pediatric and
congenital heart disease (CHD) patients undergoing VAD
implantation. The purpose of this document is to provide
expert-consensus derived recommendations and whenever
possible, these recommendations shall be guided by evidence. The creation of this consensus document required
multiples steps including the engagement of the ISHLT
councils, identification and selection of experts in the field,
and the development of 13 Tasks Forces. Extensive
1

Indicates co-first authors.
Indicates Co-Editors.
Reprint requests: Angela Lorts MD, MBA, Cincinnati Children’s Hospital, University of Cincinnati, 3333 Burnet Avenue, Cincinnati, OH,
45209. Telephone: 513- 803-4580.
E-mail address: angela.lorts@cchmc.org
2

literature searches were performed but due to the lack of
comparative trials in pediatrics, this document was written
as a literature review with expert opinion rather than based
on level of evidence.

Patient selection
Timing of VAD
Optimal timing for the implantation of a VAD in pediatric
patients should be determined by an assessment of the
potential risks and benefits of the intervention. The complexity of this decision-making is amplified by the numerous variables impacting VAD risk profile, including patient
age/size,3-5 anatomy,6-8 developmental hemostasis,9 and
device type,10-12 as well as factors related to illness severity
and comorbidities prior to implantation.7,11,12 Many of
these factors are interdependent. Paracorporeal devices are
most often placed in younger, smaller patients who are
more likely to be sicker, have CHD, and end-organ dysfunction at the time of VAD implantation, making it difficult to assess which of these factors drives inferior
outcomes.11-13 While this complex reality precludes the formulation of any generalizable guidelines for the optimal
timing of VAD placement for all pediatric patients, one
consistent theme to emerge from the literature is the inferior
outcomes of VAD support for pediatric patients in cardiogenic shock (INTERMACS Profile 1) or with end-organ
dysfunction prior to implant.11,12,14 (Figure 1) Despite these
data, the most recent Pedimacs report reveals that 33% of
patients are still INTERMACS Profile 1 at the time of
implant, including 40% of patients receiving paracorporeal
pulsatile devices, 49% of patients receiving paracorporeal
continuous flow devices, and 19 % of patients receiving
intracorporeal continuous flow devices .12 Similarly, the
last Paedi-Euromacs report showed that 21% of patients
were implanted as INTERMACS Profile 1.15
Although, patients have better outcomes if implanted
before they become too ill, there are times when pediatric
patient present in cardiogenic shock and/or with end-organ
injury. In these cases, attempting to reverse the shock process before implantation of a durable VAD may possibly
result in better outcomes. The role of paracorporeal
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Figure 1

711

Survival curves from 3rd Annual Pedimacs report.12

continuous flow (CF) and percutaneous VADs, or venoarterial extracorporeal membrane oxygenation (ECMO) in stabilizing/salvaging critically ill pediatric patients with
advanced HF to make them better candidates for long term
support is not well understood to date. There is evidence
that end-organ dysfunction in children can improve significantly with a paracorporeal CF device and this may have a
beneficial effect on outcomes.16,17,18 ECMO support prior
to VAD implantation has not been associated with better
survival post VAD,8,12 although it is difficult to separate the
impact of ECMO from the level of illness requiring ECMO
in interpreting this data.

Indications for VAD
Failure of medical management: In many cases, medical
management does allow stabilization of patients with HF.
In some cases, HF progresses and VAD therapy is the only
option for stabilization. Progressive respiratory (requiring
non-invasive and invasive support) decompensation, liver
dysfunction, kidney injury and feeding intolerance are commonly reported measures of congestion and/or inadequate
cardiac output (CO) that may develop despite optimal medical management. End-organ dysfunction is common in
pediatric VAD patients prior to implantation, with 45% of
patients intubated (paracorporeal devices 75-85% of
patients compared to intracorporeal devices 21%), 94% on
inotropes, 64% requiring feeding tubes/TPN, 40% with
hyperbilirubinemia and 30% having a glomerular filtration
rate (GFR) < 60 mL  min 1 1.73 m.2,12 These findings

are notable given end-organ dysfunction is associated with
poor outcomes among VAD patients and following
transplantation3,7,14,18 and timely implantation can result in
reversal of end-organ dysfunction and better outcomes.16, 19
Post-cardiotomy failure to wean from cardiopulmonary
bypass (CPB): The presence of a previous sternotomy or
additional cardiac surgery in pediatric VAD patients ranges
from 23% to 39%.12,20 Post-cardiotomy patients (in most
circumstances those with CHD), who fail to wean from cardiopulmonary bypass (CPB) are more likely to be converted
to ECMO or implanted with paracorporeal CF devices.
With respect to the use of more durable VADs, failure to
wean from CPB or decompensation during the index hospitalization after cardiac surgery is a significant risk factor for
mortality among patients supported with a EXCOR.7
Uncontrollable Arrhythmias: Cardiogenic shock from
uncontrolled tachyarrhythmia is rare and most of the literature pertaining to mechanical circulatory support (MCS)
involves case reports and the use of ECMO. VAD support
was deemed necessary in 10% (n = 39) of patients in the
only multicenter retrospective review21 of pediatric patients
with arrhythmias.

Intent of VAD
The primary indication for pediatric VAD use in North
America remains BTT, with 55% of patients listed at time
of implantation and 34% being assessed for candidacy.12
Additional, implantation strategies include bridge to recovery (BTR) (6%), and destination/chronic therapy (DT) (2%)
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and other (3%).12 Similar frequency of intent has also been
recently reported in the second Paedi-EUROMACS report
with 85% of patients implanted with an intention to transplant with 56% BTT and possible BTT 29%.15 Although
most patients are implanted with the intent to transplant,
pediatric DT is becoming more common especially in
patients with muscular dystrophy (MD) and congenital
heart disease (CHD) patients.22-25

Pre-implant planning
End-Organ Assessment: Although pre-operative renal,
hepatic, respiratory and nutritional failure have been associated with worse post-VAD outcomes, many patients have
pre-operative end-organ dysfunction.26 This likely is due to
late presentation, late diagnosis or delayed timing for
implantation. Irreversible renal dysfunction has been considered a relative contraindication to VAD implantation in
the past but identifying irreversible dysfunction remains a
significant challenge. Current data is complicated by various definitions of renal dysfunction including: serum creatinine > 1.6 mg/dl for patients aged > 10 years, or creatinine
> 1.0 mg/dl for patients aged ≤ 10 years, or by the estimated glomerular filtration rate (eGFR) using the Schwartz
formula3,11,12 being < 90 ml/min/1.73 m.2 In the 3rd Pedimacs report, the threshold was defined as <60 mL/min1/
1.73 m2 and found that 30% of patients had renal insufficiency with 5% found to have an eGFR <30 mL/min1/1.73
m2 or requiring dialysis.12 Post-VAD outcomes have been
shown to be worse if the patient has renal dysfunction prior
to VAD implantation.16,27
Congestive hepatopathy resultant from HF has also been
associated with both morbidity and mortality post-VAD.
Elevated ALT/AST values are reported in up to 22% to
25% of patients, and abnormal bilirubin in 40% to 45% of
patients at the time of VAD.3,11,12,14 Mortality has been
shown to be higher in patients with elevated bilirubin levels, and is particularly high for patients with additional risk
factors, such as patients, weighing less than 10kg (mortality
70%).3,14
The use of mechanical ventilatory support is reported in
up to 45% to 49% of patients with 23% to 27% requiring
ongoing medical paralysis at the time of VAD implantation.11,12 However, significant differences are seen between
the device type implanted, with only 21% of intracorporeal
CF-VAD patients intubated at the time at implantation.12
Poor pre-operative nutrition secondary to poor appetite,
abdominal discomfort and nausea may represent symptoms
of inadequate gut perfusion from low CO states or venous
congestion. The presence of tube feeding, TPN or a combination of both has been reported in up to 64% of patients
undergoing VAD implantation.12
Right Heart Assessment: “Right heart failure” (RHF) in
children after LVAD implant is difficult to quantify, but has
been shown to have an incidence as high as 42%.28
Although right ventricular dysfunction is common, this can
typically be managed medically as BiVAD is relatively
uncommon in the pediatric VAD population (15% of

patients in the most recent Pedimacs cohort).26 Many clinical and imaging parameters have been used to assess the
right ventricular (RV) function prior to VAD, however
none of the individual parameters have been a sole predictor
of the need for RV support. Echocardiography may be used
to qualitatively assess RV systolic function, and semi quantitative measures such as tricuspid annular plane systolic
excursion (TAPSE) and RV fractional area change can be
used for RV functional assessment; however, the value of
any individual echocardiographic parameter in predicting
RV failure and/or the need for BiVAD support is limited.29
Estimation of RV pressure through measurement of tricuspid regurgitation jet velocity and position of the inter ventricular septum can also be used to screen for elevated
pulmonary arterial pressures as an indicator of elevated pulmonary vascular resistance (PVR). Cardiac catheterization
to measure CO, central venous pressure (CVP), and pulmonary capillary wedge pressure often occurs prior to VAD
placement, but this is neither practical nor safe in all
patients. Finally, assessment of cardiac rhythm is imperative. Sustained ventricular arrhythmias not controlled by
pharmacologic measures may contribute to RHF and need
for BiVAD support in the perioperative period.30,31 Numerous clinical, imaging, and hemodynamic parameters have
been identified in the adult VAD literature as tools for
predicting the need for BiVAD support; these include preoperative mechanical ventilation, preoperative renal
replacement therapy, elevated CVP, and severe RV systolic
dysfunction.32 In the pediatric population, data regarding
these variables are more limited, but include preoperative
ECMO and elevated blood urea nitrogen.28 Despite these
parameters, the decision to proceed with BiVAD support is
typically made intraoperatively. If RVAD support is
needed, temporary RV support may be considered to allow
RV recovery following CPB and decompression of the RV
and improvement of fluid overload.33
Support Type Assessment: After establishing that a
patient requires a VAD, an important subsequent step is
determining the kind of support needed. This refers to the
support of the systemic or LV alone (SVAD or LVAD) versus biventricular support (BiVAD). While support of the
RV alone (RVAD) may also be considered, it is uncommon.
Consideration of LVAD versus BiVAD support is relevant
only to patients with biventricular circulations. For patients
with single ventricle circulation, however, it is critical to
recognize that adequate support of the circulation with a
systemic VAD (SVAD) may result in suboptimal outcomes
if the patient’s circulatory derangement results wholly or in
part from perturbations in the Fontan pathway.34
Psychosocial Assessment: A thorough patient and family psychosocial assessment is critically important preVAD implant. The goal of the psychosocial assessment is
to identify patient and family strengths, weaknesses and
intervention needs, particularly as they relate to VAD care
demands. Similar to pediatric pre-heart transplant listing,
primary domains of the pre-VAD psychosocial evaluation
should minimally include: patient and family treatment
adherence, barriers to medical management, disease and
VAD-related
knowledge,
cognitive
and/or
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neurodevelopmental functioning, current and historic mental health, substance use, social support, family functioning,
and abuse and legal history.35,36
Device “fit”: Innovative imaging techniques using virtual
device implantation have become available and evolved as
an accepted pre-operative planning tool.37-40 This is especially relevant to children that are being considered for a
device that has been U.S. Food and Drug Administration
(FDA)-labeled for a larger-sized patient. Accurately scaled
3-dimensional (3D) surface rendering of the device are
placed within a 3D reconstruction of the chest to assess for
individual fit. Thus device compression of pertinent intrathoracic structures may be ruled out as well as assessing the
ability of the inflow cannula to fit within the ventricular cavity.41 It must be emphasized that these virtual assessments
are typically performed on the preoperative geometry of the
heart. Cardiac geometry, however, can be significantly different once decompressed with VAD, which has become more
predictable as experience has increased.

Key Points

 In general, VAD implantation should be considered,
prior to significant end-organ dysfunction or clinical
deterioration.
Table 1
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 Patients in cardiogenic shock, or INTERMACS Profile 1,
have increased mortality rates post VAD therefore stabilization prior to durable support should be considered.
 Pre-implant planning is a key step in determining eligibility for VAD therapy and should include assessment of
end-organs, surgical planning and psychosocial
assessment.

Device selection
Devices available for children with end-stage HF can be
classified in a number of ways (Table 1). They can be
dichotomized by anticipated duration of therapy (temporary
or durable) or by design and function (PF or CF). Devices
can further be separated by site of implantation (paracorporeal, extracorporeal, intracorporeal, or intravascular) as well
as by what form of circulatory support they provide: LV,
RV, SV, BiV or total heart replacement (TAH).
Pulsatile Flow Devices: The Berlin Heart EXCOR (Berlin, Germany) is a pneumatically driven paracorporeal
VAD, which has been the mainstay of support throughout
the world for children for over two decades. In the U.S., the
EXCOR is the only device FDA-approved VAD for children. The EXCOR pump comes in a number of sizes
(named after their stroke volume) allowing support of children and adults across a broad weight range (3 kg and

Devices Used in Children and Adolescents

PC, Paracorporeal; CF, Continuous Flow; IC, Intracorporeal; IV, Intravascular; C, Corporeal
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greater). However, the device is being used most frequently
in children <20 Kg.12 Various implantation options are
available and the pump can be used to as a LVAD, RVAD,
SVAD or BiVAD configuration. The EXCOR can only be
used for inpatients in the U.S., but other countries allow
patient discharge on a mobile driver. The Syncardia (tTAH, Tucson, Arizona, USA) is a pulsatile, durable device
that is intracorporeal and pneumatically driven. The device
provides biventricular support following cardiectomy. In
the pediatric and CHD population, it has played a role in
many scenarios including support of the patient with graft
failure post-transplant (as immunosuppression can be withdrawn after TAH implantation) and support of complex
CHD including the Fontan circulation.42-44 Only two sizes
of device are available, both FDA approved, one with
70 mL chambers and one with 50 mL chambers. The
smaller device used in patients with a Body Surface Area
(BSA) <1.5m.2 The device was developed with intent to
discharge patients post-implantation, and hence mobile
drivers exist for use out of the hospital.
Continuous Flow Devices: Various paracorporeal, temporary pump heads are available that can be used to provide
support of either or both ventricles in children. The most
commonly used pumps are the RotaFlow (Maquet) centrifugal pump and the Centrimag/Pedimag (Abbott Laboratories) magnetically levitated devices. In either case, various
cannulas can be used to surgically connect the pump head
to the circulation allowing flexibility in application and the
potential to initiate support without going on cardiopulmonary bypass. This flexibility makes these devices useful for
both recovery and in challenging settings such as CHD.
While these devices are by their nature temporary forms of
support that require in hospital admission, they may be utilized as a long-term BTT or BTR.45,46 Other products exist
as short-term circulatory support devices primarily targeted
at circulatory rescue in adults. The TandemHeart is an intravascular device connected to a centrifugal pump that can be
placed intravenously to support the RV with ejection to the
pulmonary artery (or the LV through a trans-septal
approach) and has been used in pediatrics as an extracorporeal device for Left Ventricular (LV) support and Single
Ventricular (SV) support.47,48 The Impella (Abiomed)
device, available in multiple sizes, is also an intravascular
device with an axial pump designed to be placed across the
aortic valve and into the LV to allow short term emergent
ventricular support.49 The Impella can also be used for RV
support, although there is limited experience in pediatrics.
Various intracorporeal durable devices are available for
adults and are also used (off-label in the U.S.) for larger children and adolescents in many countries. The current implantable continuous flow (CF) devices includes the axial flow,
HeartMate II, (Abbott Laboratories, IL, US), centrifugal
hydrodynamic flow HVAD System, (Medtronic, Minneapolis, MN, US) and centrifugal full-mag Lev HeartMate 3
(Abbott Laboratories). These devices are designed for longterm support and are implanted with the intention to discharge. The size of these devices limit their use in children
and implantation is generally considered at >15 -20 kg
(although smaller implantations have been described).50,51-53

The HVAD device has been utilized more frequently in
smaller children due to the size of the pump, although the
new HM3 has gained attention in children due to its shorter
inflow and favorable adverse event profile.53,54 Similar to the
adult intracorporeal devices, a miniature CF axial pump, the
Jarvik (Jarvik Heart Inc, New York City, New York, USA),
is currently under study through an industry collaboration
with the NIH (PumpKIN trial).55

Key Points
 After the decision to place a VAD has been made, the
next crucial step is to determine the level of support
needed (LVAD vs SVAD or BiVAD in biventricular
circulation).
 Important considerations for device selection include
patient-device size matching; implant configuration
LVAD, SVAD or BiVAD); duration of support and support intent.
 VADs can be broadly characterized by duration of support (temporary vs durable), design (pulsatile vs continuous flow), or site of implantation (paracorporeal,
intracorporeal, or intravascular).
 Currently intracorporeal CF devices are generally considered in children >15-20kg and use has been increasing
over the last decade. The Berlin EXCOR is used mostly
in children <20kg. The paracorporeal continuous flow
devices are used in patients that may recover, those that
need BiVAD support and as a BTT in some high-risk
populations such as small children with CHD.
 TAH can be used in children but has mainly been used in
unique situations such as complex CHD and transplant
graft failure.

Operative management
Optimal surgical technique depends on the device and the
patient’s unique characteristics. In children, challenges due
to anatomic and pathophysiologic variations remain.56
Surgical Considerations: Achieving an ideal inflow
configuration is vital and dependent on the patient’s anatomy. When positioning an apical cannula, regardless of
whether it is an intracorporeal or paracorporeal VAD, the
cardinal rule is to position the inflow cannula parallel to the
interventricular septum, facing the systemic AV valve.
With dilated ventricles, apical cannulation is less challenging; however, in non-dilated hearts such as restrictive,
hypertrophic cardiomyopathy or CHD this can be more difficult. In these cases, strategies to accommodate the LV apical cannula including extended LV myectomy, mitral valve
leaflet/apparatus excision and even prosthetic valve removal
have been successfully reported.57 However, for the restrictive and hypertrophic diagnoses apical cannulation may not
ideal due to contraction around the inflow cannula
compromising flow. Alternatively, an atrial cannulation may
be considered. This strategy also has the benefits of avoiding
a ventriculotomy, and the use of CPB.58 The next challenge
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can be the outflow graft anastomosis to the ascending aorta
due to the length and diameter of the vessels. Several modifications have been reported including the interposition of a
vascular graft between the outflow cannula tip and the aortic
wall or the innominate artery.59 In general, the outflow graft
cannula should be positioned as proximal as possible to aid
with future transplantation; but making sure it does not
impinge on the right ventricle especially with the EXCOR
cannulae. Therefore, it should be placed about 45 degrees off
the anterior surface of the aorta to the patient’s right.
Pediatric alternatives to inflow implantation sites have
include utilization of the diaphragmatic surface of the LV. 60
Such a technique may not be suitable in small pediatric
hearts because of the risk of posterior descending coronary
artery injury with the sewing ring and/or sutures.61 Some
authors describe creation of a small pocket above the left
hemi-diaphragm while coring the LV apex.61 Placing the
pump in the pocket requires relocation of the LV apex medially and caudally, which orients the inflow cannula in a
more vertical plane, parallel to the interventricular septum.61
For RVAD placement, there are three sites for potential
implantation: (1) the right atrium (standard site for
EXCOR), (2) the diaphragmatic wall or (3) the free wall of
the RV. The location depends on the device and cannulas
selected. The EXCOR cannulas are tunneled through the
skin and secured on the RA free wall directly opposite the
tricuspid valve. For all implant sites, correct orientation of
the inflow cannula is crucial to ensure unobstructed flow
into the pump. The outflow graft is tunneled through the
skin and is anastomosed (with or without a graft extension)
to the pulmonary artery.
Driveline and cannula exit sites are important to plan
before incision. For the EXCOR, the LV apical cannula
must exit at a few cm below the left costal margin at or lateral to the mid-clavicular line. The LVAD arterial outflow
cannula exits a few cm below and to the right of the xiphoid
process. An RVAD outflow cannula to the pulmonary artery
would be to the left of the midline and the inflow cannula
would exist to the right of the LVAD aortic cannula. For
proper connection the cannula have to cross either outside
the body or within the chest. The latter is rarely done and is
in not practical in those less than 10kg. The crossing of the
outflow cannulae externally on the upper abdominal wall
results in the LVAD EXCOR pump laying upside down
(blood side up) compared to the right pump. At least several
cm of skin should be preserved between adjacent cannulae
exit points to prevent erosion and breakdown. Furthermore,
the Dacron cuff on each cannula should extend at least
1 cm beyond the skin exit site to allow for tissue in growth.
There are times when concomitant surgery must occur.
The most common is aortic and atrioventricular (AV) valve
repair. Presence of significant aortic incompetence should
be addressed with replacement, repair or over-sewing at the
time of VAD implantation regardless of chosen device. AV
valve stenosis has to be avoided when implanting the inflow
cannula into the ventricle but there are mixed reports of
treatment of AV valve regurgitation including AV valve
repair, replacement or removal.
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In all pediatric VAD patients, determination of the presence of intra and extracardiac shunts is required.38,62-65
While some surgeons leave a small Patent Foramen Ovale
(PFO) or atrial fenestration intentionally, especially in the
Fontan patients, larger intracardiac communications should
be closed either percutaneously or at time of VAD placement to avoid cyanosis.38
Perioperative antimicrobial prophylaxis should be targeted to skin flora as the most likely contaminants of the
surgical site. Limited data are available in pediatric VAD 66
and no randomized data exists looking at surgical prophylaxis for pediatric VAD. Recommendations are based on
available guidelines, including ISHLT, for adult VAD
therapy.67

Key Points
 When evaluating for a durable VAD it is important to
review cardiac morphology and physiology data, including the presence of shunts, collateral vessels, and the
location and course of great vessels.
 In pediatric patients with residual shunting, shunt closure
(exceptions may exist in the Fontan patients) should
occur at the time of VAD implant.

Post-operative hemodynamic goals
Device settings should be optimized in the operating room
with both TEE and hemodynamic monitoring before and
after chest closure. After returning to the ICU, the primary
postoperative goals are to obtain sufficient systemic perfusion and maintain normal systemic and venous pressure
while avoiding VAD-related complications. Establishing
appropriate device settings requires identification of physiologically appropriate CO goals as well as careful assessment of imaging and hemodynamic parameters. In
biventricular physiology, the goal CI is commonly 2-3 L/
min/m2. In the case of single ventricle physiology, a much
higher CO goal to achieve pulmonary venous unloading
and optimal end-organ perfusion may be needed.68
For the EXCOR, pump parameters should be manipulated to maintain a full device fill and ejection with each
cycle. The maximal output of the device is calculated by
the product of the device size (stroke volume) and set rate.
The actual output is generally less, but difficult to accurately estimate given the volume of a half sphere is related
to the radius to the third power. Several strategies targeting
both the patient and the device can be employed to increase
fill and thus increase output when desired. Decreasing the
percent systole, the rate and diastolic pressure will increase
the time spent in diastole and thus device filling, but this
must be balanced by a commensurate increase in systolic
pressure to ensure full device emptying. The broad availability of digital photography/video, particularly slowmotion, has emerged as a useful tool for assessment/
troubleshooting.
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For all of the CF devices, optimizing CO must be accomplished by optimizing preload and afterload while simultaneously preventing excessive leftward interventricular septal
shift. Each pump is developed to function within a given
range of power consumption for a given impeller/rotor set
speed. When the relationship of these indices falls outside of
that which is expected, an underlying etiology should be
sought (excessive/ineffective pump speed, device thrombosis, device malfunction, etc.). Patient management should
take into account the interaction between native cardiovascular system, physiology and device function. Though each
device intrinsically has a unique pressure-flow response (H:
Q) curve, all are innately sensitive to afterload. During diastole there is a large difference in pressure across the pump
and therefore lower flow, while during systole the differences
is smaller producing a higher flow state.
For BiVAD support, an imbalance can occur in flow of
the pulmonary versus systemic circulation resulting in
venous congestion upstream from the relatively under-supported circuit. As such, when RVAD output overwhelms
that of LV support, pulmonary edema ensues. Alternatively,
when LVAD support is in excess of RVAD support,
hepatic, renal and digestive dysfunction may become apparent. Once biventricular support is balanced and unobstructed, the hemodynamic management is focused on
avoidance of hypo- or hypervolemia and afterload reduction
to achieve a normal CO.

Key Points
 EXCOR settings should be targeted to allow a full fill
and ejection with each cycle, use of digital image capture
with slow-motion can aid in the assessment of membrane
movement.
 CF device support parameters should be individualized
to physiologic support needs and optimized not only
through changes in parameters but also manipulation of
afterload and preload.

Anticoagulation management
Post-operative Hemostasis: Bleeding is a significant issue
following VAD implantation. The risk for bleeding stems
from disturbances in the coagulation profile in pediatric
patients and are related to developmental hemostasis, heart
failure cachexia, liver dysfunction, and coagulation factor/
platelet consumption. Coagulation deficits including thrombin generation factors, adhesive proteins concentrations
[fibrinogen and Von Willebrand factor (VWF)], and platelet
function should be regularly assessed and normalized to
stop bleeding. Thromboelastography (TEG) and ROTEM
can diagnose specific deficits in the early post-operative
phase. Factor deficiencies resulting from blood and volume
administration must be avoided through concurrent use of
blood products, coagulation concentrates, and other hemostatic agents guided by functional hemostatic evaluations.
Anticoagulation may be considered only after achieving
hemostasis.

Developmental hemostasis: There are qualitative and
quantitative changes in hemostasis from fetal to adult life
making following adult anticoagulation protocols difficult
in pediatric VAD. For example, infants and adults may
share similarities in size and numbers of platelets but their
pharmacological responses vary. The response to agonists
may be decreased in neonatal platelets compared to adults
and more so in pre-term infants. However, despite blunted
reactivity, infants compensate by having higher levels of
VWF and multimers in addition to the higher hematocrit.69
As well, in the neonate, the plasma levels of pro-coagulant
factors (which are produced by the liver), including the
vitamin-K dependent ones, are at approximately 50% of
what an adult may have. This reflects the differences in neonatal and adult partial thromboplastic time (PTT).70 Furthermore, the concentration of antithrombin (AT3), protein
C and S are lower in infants compared with adults, and
infants have a reduced ability to break down fibrin due to
decreased levels of plasminogen. The changes in AT3 concentrations in neonates have led to difficulty with titration
of heparin.
Anticoagulation and Antiplatelet Therapy: Historically,
unfractionated heparin (UFH), low molecular weight heparin (LMWH) and vitamin K antagonists (VKA) have been
the standard of care for paracorporeal and intracorporeal
VADs in children.71-73 However, there has been a shift
towards increased use of direct thrombin inhibitors (DTI),
namely bivalirudin, for anticoagulation, especially in the
setting of paracorporeal VAD support.74-76 Centers have
also reported modification of the traditional antiplatelet
therapy, with weight-based dosing of anti-platelet drugs in
paracorporeal PF devices being associated with lower
stroke rate.77
Monitoring of anticoagulation and antiplatelet therapy
remains a challenge, with limitations surrounding the consistency and interpretability of all laboratory tests. UFH can
be titrated using activated prothrombin time (aPTT) or antiXa level. LMWH is titrated to anti-Xa levels, while VKA is
monitored via International Normalized Ratio (INR) with
device specific ranges.73,78, 79 DTI can be monitored using
aPTT and dilute thrombin time (dTT). The DTI appear to
have more linear and predictable dose response curves.78 In
pediatrics, antiplatelet titration used to be heavily dependent upon Thromboelastography (TEG) with platelet mapping (TEG PM), however recent studies have demonstrated
less dose response correlation with platelet mapping.80,81
VerifyNow and Platelet Function Analyzer-100 (PFA-100)
have been used to assess antiplatelet agent resistance; however these have yet to be validated in a pediatric population.81 Many medications (i.e. Milrinone, nitroprusside and
inhaled Nitric Oxide) used to support VAD patients have
been shown to inhibit platelet function.82-84
Effect of inflammation and infection on anticoagulation: Due to the shared nature between inflammation and
anticoagulation, derangement of the normal coagulation
function can occur during infection/inflammation. There
are several markers of inflammation that can be used clinically including white blood cell counts, platelet counts, Creactive protein, fibrinogen, and the presence of fevers,
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though it is not clear which marker is associated with the
greatest likelihood of a bleeding or clotting complication.
From a practical standpoint, the presence of fevers (in the
absence of infection), elevated C-reactive protein levels,
and elevated fibrinogen levels may lead to a change in anticoagulation or the addition of corticosteroids.77,85 While
the data are limited regarding the efficacy of this therapy,
there are small single-center studies that suggest steroids do
decrease markers of inflammation and may decrease the
incidence of stroke in patients on EXCOR support.85,86

Key Points
 In North America, there is a shift towards the use of DTI
therapy for paracorporeal VAD support in children.
 In EXCOR patients, post-VAD inflammation may
increase the risk of thrombosis, bleeding and stroke and
steroids have been used in small single center cohorts to
treat the inflammatory state in an attempt to decrease the
incidence of stroke.

Adverse events
See Table 2 from Pedimacs report for common adverse
event rates.26
Infection: Infection remains a significant complication
following implant of VADs. These infections are grouped
according to ISHLT infection guideline nomenclature67 as
non-VAD (i.e. pneumonia), VAD-related (i.e. infective
endocarditis or mediastinitis) or VAD-specific infections
[driveline infections (DLI), pocket infections and pump

Table 2

Adverse Event Rates from Pedimacs 3rd Annual Report26
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infections].87 Infections account for about 17% of all the
adverse events (AE) with these events more commonly
occurring >3 months post implant and accounting for
nearly 1 out of 3 of readmissions following
discharge.66,88,89 Identified risk factors of infections have
included: time on device, prior infection and prior noninfectious adverse events.66,88 Single-center studies report
that approximately 15% - 50% of patients will develop a
DLI.90-100 The EXCOR trials suggest that while infections
overall are common (occurring in 41% - 63% of patients),
cannula infections are less common (0% -17%).71,101 While
early reports suggested that infection was not associated
with decreased survival, recent data from Pedimacs suggests an increased mortality with infection in patients on
CF devices.66,102 In the Pedimacs data, 77% of infectious
AEs were treated with intravenous antibiotics, 11% with
oral therapy and 8% required both surgical and antimicrobial therapy.66 Adult-focused recommendations suggest
management be based on the site and extent of the infection
with consideration for secondary prophylaxis in some
patient awaiting transplantation.67 Prevention of VAD-specific infections relies primarily on infection control
principles.67
Right Ventricular Failure (RVF): RVF is manifested by
elevated CVP, liver dysfunction, ascites, and renal injury. It
usually occurs within 2 weeks of LVAD implant and is
associated with both morbidity and mortality.103,104 In
adults, early RVF is defined as use of inotropes > 14 days,
inhaled nitric oxide > 48 hours or unplanned RVAD. Incidence of early RVF in adults with CF-VADs is 15% to 40%
but may be lower in children.32,105-108 Etiology of RVF is
multi-factorial with contributing factors including shift of
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the interventricular leftward, increased RV preload, and
arrhythmias.104,109
A major pre-operatively goal is to implant LVAD before
RVF develops, and, if already present, to optimize RV
hemodynamics before LVAD implantation.104,110 Aggressive pre-operative management of patients with RV dysfunction should focus on diuresis (goal CVP < 15 mmHg),
institution of milrinone § epinephrine for contractility, and
pulmonary vasodilators to reduce RV afterload.
Intra-operatively, TEE monitoring of RV function
should occur during LVAD implant.104 Strategies to preserve RV function include: maintenance of adequate blood
pressure, avoidance of pulmonary vasoconstriction and use
of pulmonary vasodilators, use of continuous ultrafiltration
during bypass, minimization or avoidance of cross clamp
time, judicious use of blood products, arrhythmia control,
consideration of delayed sternal closure, and maintaining the
septum in a midline position.111-114 If RVF occurs, elective
early rather than delayed emergent mechanical RVAD support has been associated with improved outcomes.115-117
Such short-term RV mechanical support options include paracorporeal CF VADs, percutaneous VAD, and ECMO; longterm RV support includes biventricular durable intracorporeal CF, TAH, or PF VAD devices.118,119 Post-operatively,
signs of RVF include decreased LVAD flow, suction events
and decreased CO, acute kidney injury, and hepatic dysfunction. Management should incorporate aggressive use of pulmonary vasodilators as well as inotropes for RV CO support
and avoidance of bradycardia until RA pressures are near
normal. RV preload should be optimized with diuresis or
hemodialysis to maintain CVP < 15 mmHg. Maintenance of
sinus rhythm should be aggressively pursued.
Pump thrombosis (PT): PT is a less common but a significant complication of VAD therapy. It results from a
variety of patient and pump factors and can develop slowly
over time or have a rapid onset. The definitions and recognition of PT vary by device type with the current EXCOR
pumps allowing visual inspection and intracorporeal pumps
requiring a combination of abnormal VAD parameters, lab
values consistent with hemolysis or symptoms of HF; with
conformation only occurring if the pump is removed.
Symptoms of hemolysis can include scleral icterus, dark
urine (hemoglobinuria), and fatigue with signs including
one or more of the following: elevated serum Lactate Dehydrogenase (LDH) (most sensitive marker), elevated plasma
free hemoglobin, and low haptoglobin.120 Recent studies
have shown the rate of PT in adults to be 4-8% in HeartMate II and HeartWare 121,122 and 1% in the HM3
device.123 PT in the pediatric patients with a CF-VAD
occurs in 11% - 44% of patients, with the largest series
reporting a rate of 15%.10,51,52,124
Management of PT in adults has largely been based on
expert opinion with published algorithms focused on both
the device type and presentation.125,126 These algorithms
focus on both medical and surgical interventions, with medical management including augmentation of anticoagulation (ex: Heparin or Bivalirubin) or antiplatelet agents (oral
or intravenous), use of thrombolytic therapy and surgical
management including pump exchange, heart transplant

(HT), or explantation.125-130 The choice between medical
and surgical management depends on device type, stage of
pump thrombosis, clinical presentation and potential complications of treatment. As there are few reports in children,
it is unclear whether these strategies are applicable to pediatrics. One potential approach in pediatrics is to initiate
heparin or Bivalirudin with rising LDH with or without
changes in pump parameters. If no response and ongoing
increases in LDH with changes in the pump parameters, in
some institutions, low dose systemic tPA could be considered if no contraindications exist.128 Lastly, if there are contraindications to tPA, evidence of rapid progression or no
response to any of the above treatments, pump exchange
should be considered.128 In some institutions pump
exchange occurs without a trial of tPA.
Neurological Events and Stroke: Device-related neurological events (NE) as defined by INTERMACS include:
cerebrovascular accidents (CVA), seizures, encephalopathy, asymptomatic neuroradiological findings, confusion
and extra-axial bleeding. Using this definition, NE comprise
12% of all adverse events and tend to occur early (23%
within 3 months vs 5% thereafter).124 NE are more common
in PF VADs (early 19.6 and late 5.6 events per 100 patientmonths) vs. CF VADs (early 4.1 and late 0.7 events per 100
patient-months). However, patient characteristics differ
between those receiving PF vs CF devices and in turn event
rates are likely not solely related to device type. Ten percent
of patients with intracorporeal CF devices had strokes, compared to 24% among paracorporeal CF and 21% among PF
devices with most being ischemic.26,45,51 The ACTION
Network has recently undertaken a multi-center quality initiative (QI) to decrease stroke rates through use of standardized blood pressure goals, meticulous anticoagulation
including DTI and improved communication between
teams.77,131
Additionally, VAD-related stroke management has challenges in pediatrics due to lack of standardized protocols.
The ACTION Network has recently developed a stroke
management bundle aimed at developing algorithm for
pediatric stroke management. This emphasizes early recognition of stroke symptoms as critical, urgent neurological
evaluation including a non-contrast head CT (within 30
minutes). If non-contrast head CT is negative but neurological symptoms persist, consideration should be for a CT
angiogram. Institution of neuroprotective measures, intracranial pressure monitoring and potential interventions
including thrombectomy or cranial decompression may be
considered. In setting of ischemic stroke with evidence of
vessel occlusion and large territory involvement, thrombectomy or intravenous tPA may be potential options for intervention.132-134 For patients with paracorporeal VAD, pump
exchange should be considered if there is evidence of a
clot. Anticoagulation management after VAD-related CVA
is challenging. If invasive interventions are being considered, or for large territory ischemic strokes with high risk
for hemorrhagic conversion, holding and potentially reversing anti-thrombotic therapy should be discussed. In setting
of hemorrhagic stroke, if bleeds are small without neurological deficits, antithrombotic therapy should be held and
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resumed if stable neuroimaging and neurological exam.
However, if there is interval expansion or large hemorrhagic involvement, antithrombotic therapy should be held
and potentially reversal. Timing of re-initiation of antithrombotic therapy should be discussed among care team
with consideration of repeat CT after initiation.
Bleeding : Bleeding is a major complication of VAD
implantation and affects approximately 30% of pediatric
patients.2,124 The highest hazard for bleeding is in the
immediate perioperative period when patients are
extremely susceptible from suture lines and dissection
planes.2,124 Bleeding is diagnosed when chest tube output is
excessive and drops in hemoglobin necessitate transfusion.
Bleeding can lead to pericardial tamponade when blood is
not adequately evacuated via chest tubes. In LVAD
patients, the initial clinical presentation of pericardial tamponade is typically an increase of CVP, followed by a
decrease in LVAD flow (depending on the amount of RA/
RV compression). As a consequence, blood pressure is usually decreased and frequently vasoactive substances have to
initiated or increased. Other clinical signs for the impaired
hemodynamic state are decrease in urine output and rise of
serum lactate. The clinical presentation of tamponade in
BiVAD patients can be very vague. Often, only an increase
of CVP is initially observed which can early on be accompanied by a decrease of urine output (due to elevated CVP).
Adequate hemodynamics can be obtained for a long time,
depending on adequate volume replacement and VAD flow
only decreases when venous return is severely compromised by compression. The threshold for surgical revision
usually is persisting chest tube output despite normalization
of coagulation parameters. Hemodynamic instability or
tamponade should prompt immediate surgical exploration.
The hazard for bleeding decreases with increasing support times.2,99,124 While perioperative bleeding usually
originates from areas affected by the VAD implantation,
late bleeding events typically affect other regions and are a
consequence of medication levels and vWF degradation
that is a result of VAD induced blood trauma. The most frequent source of late bleeding is the gastrointestinal tract,
although less frequent than the adult population.135

Support strategies for unique pediatric
populations
CF VAD in small patients: The encouraging outcomes in
adult VAD technology have had a profound impact on its use
in children. In children, with a weight >15-20 kg requiring
VAD, the use of an implantable LVAD may be feasible with
results that are non-inferior to the extracorporeal
devices,65,136,137 and discharge from the hospital is possible,
resulting in a better QoL,10,65,136,138-140 decreased costs,141
and the potential for chronic therapy. It remains unclear what
the size cut off is for the use of these devices in smaller children.142-145 The limited thoracic space might not be large
enough to ensure proper position of an intra-corporeal device.
Distortion of the rotor housing can position the inflow cannula
in a plane that significantly increases the risk of inadequate
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drainage, suction events and/or pump thrombus formation. If
necessary the pump housing may be placed in a pre-peritoneal
pocket fashioned by dividing the left diaphragm anteriorly 61
or to allow the device to sit within the left pleural cavity, caudal to the left lower lobe and posterior to the diaphragm at the
costo-diaphragmatic angle. In smaller patients, not only the
angle of the inflow cannula, but its depth in the ventricular
cavity should be considered. If placed in a small heart, the tip
of the inflow cannula may approach the mitral valve, which
could either impede mitral valve function or, importantly
obstruct the inflow cannula. Therefore LV apex to mitral
valve distance must be precisely measured on preoperative
imaging.146,147 Of note, the newer HM3 has a shorter inflow
when compared to the HVAD (22 mm vs 32.2 mm).55 Alternatively, if the mitral valve is obstructing inflow, excision of
the valve may be considered with a CF device.
Muscular Dystrophies (MD): HF is a significant cause
of mortality in patients with MD.148 Patients with MD are
often not candidates for HT because of the progressive
nature of their multi-system disease, affecting pulmonary,
neurological functioning and mobility. Some centers have
reported the use of DT VADs for medically-resistant HF in
these patient groups.25,149 The use of DT in these patients
require ethical and local institutional considerations.150
Chemotherapy-Induced Cardiomyopathies (CCMP):
Improvements in oncologic therapies has increased life
expectancy and cure rates for many types of cancer. The
cardiotoxicity risk of many chemotherapeutic regimens are
well documented.151,152 VADs have been used for DT in
patients with CCMP, or for BTT in patients with sustained
remission. Pediatric data is limited and consistent with this
being an uncommon indication for VAD therapy or
HT.153,154 In adult populations, it is estimated that 2% to
3% of patients undergoing VAD have CCMP.155 Considerations including the increased risks related to RV dysfunction, bleeding and sternotomy after radiation therapy
should be noted prior to VAD implantation.155
Support Strategies for Adult Congenital Heart Disease
(ACHD): The prevalence of HF in ACHD is diagnosis-specific, increases with age10 and exceeds that in the general
population.11 HT has been the optimal therapy for end-stage
HF in ACHD.22-25 Experience is limited using VAD and/or
TAH in ACHD patients as a bridge to transplant. Overall,
<1% of all VADs in adults are implanted in ACHD
patients. Nevertheless, ACHD patients spend more time
awaiting HT21,26,27 and the sickest are more likely to deteriorate while awaiting HT than the non-ACHD population.28,29 In this setting, VAD support has the potential for
benefit in the ACHD population26,30 without impacting
post-transplant outcomes.31 Earlier use of VAD therapy
may help to decrease the early hazard associated with HT
among ACHD patients by decreasing end-organ dysfunction and relieving pulmonary hypertension secondary to
CHD.156 Although ACHD patients that receive VAD have
an earlier rate of mortality post VAD they have similar rates
of adverse events and improved functional capacity if they
survive the first 30 days.157
There are times when an underlying anatomical issue
leads to HF in a patient with ACHD and in these cases
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correction of the underlying lesion if possible and utilization of temporary MCS strategies to support the patient
perioperatively should be considered. This approach has
been shown in select cases to lead to excellent outcomes
avoiding long-term VAD support and HT.32 Durable VADs
may still be required despite best efforts to address the etiology of ventricular failure. Underlying lesions should be corrected at the time of VAD implant including uncorrected
shunts, stenotic lesions of the left AV valve and regurgitation of the aortic valve to allow optimal VAD function. If
multiple residual lesions requiring surgical intervention are
present or BiV support may be necessary, consideration
should be given to the use of a TAH.
Use of VADs in patients with a morphologic systemic
LV is generally more conventional and fits the paradigm
of non-CHD patients. Still, additional obstacles must be
appreciated such as dextrocardia/heterotaxy syndrome and
the risk of multiple sternotomies should not be underestimated. Furthermore, the possible need for BiVsupport
should be assessed during surgical planning and be available in the operating room. Adults with a morphologic systemic RV and a sub-pulmonary morphologic LV typically
have a diagnosis of either D-TGA following atrial switch
or unrepaired ccTGA, or ccTGA following physiologic
repair. The systemic RV is predisposed to systemic atrioventricular valve regurgitation (AVVR), ventricular dysfunction, and pump failure. Outcomes of VAD support for
systemic RVF are limited to case series, but survival
appears to be acceptable.35-37 Implantation may be complicated by changes in RV anatomy; the free wall and septum
are much thicker and more trabeculated than in a normal
RV. For intracorporeal CF-devices three different implantation sites for the RV that have been reported: diaphragmatic,158,159 free wall158 and right atrium (RA).160 In
patients after Mustard/Senning operations, the free wall of
the systemic ventricle is easily accessible. Diaphragmatic
implantation can be technically more challenging, thus
carrying a higher risk of bleeding. With a ventricular
inflow position, excision of muscular trabeculae including
the moderator band from the inflow cannula site may be
necessary.161,162-164 If the RA is chosen, correct orientation of the inflow cannula is necessary with the inflow cannula being positioned toward the tricuspid valve orifice so
that unobstructed flow is possible. Resection of valve leaflets might be necessary to ensure unobstructed flow
towards the inflow cannula.

Key Points

 Patients with ACHD, refractory to medical management
should be evaluated for MCS early before progression of
end-organ dysfunction.
 Although ACHD patients have a higher earlier mortality
rate they have similar adverse event rates and improvement in quality of life when compared to non-ACHD
patients.

Support strategies for single ventricle patients
There is a wide range of CHD that result in single ventricle
physiology.165 In the single ventricle, myocardial injury,
hypertrophy, fibrosis and dysfunction often result from multiple, cumulative insults which may include volume loading, pressure loading, chronic cyanosis, coronary ischemia,
chronic upregulation of the renin-angiotensin-aldosterone
system, chronic underfilling and overlapping genetic factors
that cause CHD and cardiomyopathy.166-172 By the age of 6,
14% of HLHS patients who have undergone the Norwood
operation will develop severe HF and HF is the most common cause of death for Fontan patients.169,173 In single ventricle patients with severe, progressive ventricular
dysfunction, significant AVVR and HF refractory to maximal medical therapy, SVAD support can be considered.
Pre- or post- stage 1 palliation support strategies: HF
secondary to dysfunction or AVVR, intractable arrhythmias, RV or LV-dependent coronary circulation with evidence of ischemia or large coronary fistulae may be used as
criteria for SVAD. Successful use of paracorporeal CF
(Pedimag/Centrimag, Rotaflow) or PF VADs (Berlin Heart
EXCOR) have been described though overall outcomes
remain poor.174-176 There is increasing use of the paracorporeal CF devices with more durable cannulation in this
population.175-178 Inflow cannula is typically placed in the
common atrium post atrial septectomy and the outflow cannula is placed into the ascending neoaorta post Norwood
operation174,175 or pulmonary artery after hybrid palliation
(which may require graft extension) in HLHS.174,177 The
outflow cannula is placed in the aorta in PA/IVS both prior
to or after shunt placement.175 VAD support after the Norwood operation requires pulmonary blood flow from either
an aortopulmonary or Blalock-Tausisng (BT) shunt.175,179
Therefore if a RV to PA conduit exists, it needs to be taken
down. Following implant, a higher-than-expected cardiac
index is often required to maintain the parallel systemic and
pulmonary circulations with some centers reporting goals
of approximately 4-6 L/min/m.174,175 The balance of pulmonary and systemic circulations (Qp/Qs) and shunt size
need to be carefully considered, as a grossly imbalanced
Qp/Qs will not be remedied with a higher CI alone.
Post-stage 2 palliation (superior cavopulmonary anastomosis or Glenn operation) support strategies:
Indications for SVAD after stage 2 include poor ventricular systolic or diastolic function or AVVR with signs of
HF. Complete understanding of the etiology of symptoms,
hemodynamics and presence of aortopulmonary and venovenous collateral vessels is critical. Successful use of PF
(EXCOR)180,181 and CF VADs (both implantable and
paracorporeal)182,183 have been described and device selection depends on patient size and center experience. The
inflow cannula can be placed in the systemic ventricle or
common atrium182 and the outflow cannula is placed in the
ascending aorta. Cyanosis can persist and worsen postVAD due to right to left shunting from the IVC when there
is atrial cannulation or from venovenous collaterals. To
improve pulmonary blood flow, centers have described

Lorts et al.

Selection and management of pediatric and congenital heart disease patients

reverting back to Stage 1 circulation at the time of VAD
implant by taking down the superior cavopulmonary anastomosis and placement of an aortopulmonary or BT
shunt.183 Alternatively, others have described for those
larger bidirectional Glen patients (usually greater than 2
years-old) successful concomitant Fontan completion and
VAD implantation.184 In either situation higher than
expected VAD flows are often required if there is systemicto-pulmonary blood flow. CF devices are thought perhaps
to work better in unrepaired SV, Post stage 1 or 2 patients
because of the minute to minute changes in inflow volume
flow from systemic to pulmonary shunting (e.g. BT shunt,
AP collaterals) to which these devices can respond to unlike
the fixed volumes of the EXCOR.
Fontan patient: Fontan physiology can result in chronic
low CO and systemic venous congestion.171 There are different clinical phenotypes of Fontan circulatory failure
including decreased systemic ventricular systolic and/or
diastolic function and elevated CVP. Patients can present
with Fontan circulatory failure with or without ventricular
dysfunction. Those without ventricular dysfunction may
manifest by intractable protein-losing enteropathy (PLE),
plastic bronchitis (PB), and/or signs of significant endorgan congestion which are associated with morbidity and
mortality.185,186 Long-term, sinus node dysfunction/
arrhythmias can also contribute to Fontan patient’s morbidity.187-191
Treatment options for the Fontan patient with circulatory
failure include: optimization of medical therapies and consideration for surgical options, including Fontan conversion
for atrio-pulmonary connections, Fontan fenestration, and
heart or heart-liver transplantation.171 While outcomes for
transplantation in Fontan patients have improved,192 a
shortage of available donor hearts results in long wait times
and waitlist mortality, as well as worse HT candidates that
adversely impacts post-transplant outcomes. Given donor
shortage, there are many reports in recent years (20142019) of SVAD support for Fontan patients as
BTT.42,180,184,193-203 There are also case reports of DT
SVAD support for Fontan patients,204 as well as VAD support of the pulmonary circulation.205 Additionally, SVAD
support in Fontan patients as bridge to combined multiorgan (heart-liver, heart-kidney) transplant have not yet
been reported.
VAD referral and pre-VAD evaluation should include
the standard VAD assessment and additionally focus on
potential anatomic and physiologic barriers to SVAD support. Timing of referral is important to VAD outcomes.
Consensus from the ACTION network about referral timing
can be found on www.actionlearningnetwork.com. Increasingly recognized is the multi-organ disease associated with
long-term Fontan physiology, which should be evaluated
alongside traditional cardiac assessment in preparation for
either SVAD support or HT.171
Indications for SVAD include poor systemic ventricular
systolic or diastolic function and/or AVVR with signs of
HF. VAD support is unlikely to be useful for Fontan
patients with PB or PLE with preserved ventricular function, competent AV valve and normal filling pressures.
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Durable CF184,193-198, 204 and PF devices,180,198-201 as well
as temporary support devices,202 have been used in Fontan
patients as BTT. Recently, there has been increasing use of
durable CF devices including the HeartMate 3197 and
HVAD.184,193-196,198,204 PF devices (EXCOR) should be
considered for patients who cannot receive a durable CF
device (typically due to size).180,198-201 Right and left sided
(“biventricular”) support has been reported using the
TAH42 or BiVAD support (with EXCOR199 or HVAD194).
Inflow cannula is placed either in the systemic
ventricle184,193,194,196-198,200,201 or common atrium195,196,
198
; resection of trabeculations may be necessary, especially
for systemic RVs.184, 193,197 Resection of the AV valve has
been reported in some cases.193,195 Mechanical AV valves
can be left intact, or resected.195 Outflow graft is typically
anastomosed to the aorta/neo-aorta in the standard manner;
bioprosthetic aortic valve replacement196 or partial/complete closure of the aortic valve203 may be considered if
aortic regurgitation is a concern. Fontan fenestrations are
closed (to decrease thromboembolic risk) by some centers,
but others have found that if left open193,197 or created200
they will allow for greater unloading of systemic venous
system, particularly if there are concerns for pulmonary
vascular disease. Fenestration has anecdotally not caused
excessive cyanosis and the saturation post VAD placement
may increase significantly even if the fenestration is present
because of the overall increase in cardiac output and
decrease in central venous pressure which leads to
decreased flow through the venous collaterals.
MCS in Fontan patients has become more prevalent
recently. The multicenter data that is available includes a
recent report of adult VAD support from the INTERMACS
registry. In that report there were 17 VAD-supported adult
Fontan patients among whom there was no difference in
survival between VAD supported single ventricle subjects
and those with biventricular congenital heart disease.65

Key Points
 To support stage 1 patients with parallel circulations,
SVAD flows to achieve a higher cardiac index are often
required and a balanced Qp/Qs is crucial.
 In stage 2 patients, converting to shunted or Fontan physiology at the time of SVAD implant may be considered
for improved pulmonary blood flow.
 There is increasing experience and success using durable
VADs to support Fontan patients with HF due to systemic ventricular dysfunction.

Discharge of the pediatric patient on a VAD
Advancements in VAD technology have allowed for
improved survival, QoL, and the potential to achieve hospital discharge. Despite these advancements, fewer than 60%
of children with intracorporeal CF devices are discharged
in the US or Europe.88 Suitability for safe discharge
depends on (1) medical stability, (2) a suitable social
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context including the presence of caregivers who can be
trained to recognize and manage acute device and medical
concerns and (3) the ability to access appropriate medical
care in the community in a timely fashion.206 The latter, in
turn, requires consideration of proximity to medical care,
appropriate training of emergency response and hospital
emergency staff, and well-defined pathways for access to
the VAD team.207
As with most medically complex patients, discharge
planning for a pediatric VAD patient should begin early,
ideally at initial evaluation. This allows the multidisciplinary team to evaluate the patient, the family structure, and
available resources to develop an understanding of the
potential to achieve discharge. This evaluation allows for
early recognition and resolution of potential barriers and
setting expectations. Figure 2 is a discharge roadmap from
ACTION, which can be posted in the patient’s room and
allows the team and family to visualize progress.
In general, providing a clear training schedule for both the
child and the family consisting of short and frequent training
sessions facilitates effective training. Training may employ a
combination of didactic teaching, reading materials, and
hands on training to practice skills such as battery changes,
controller changes and self-testing. If local resources permit,
modalities such as online training, and case-based simulation
training have been effective vehicles for training in some centers though published literature is limited.208
It is expected that a caregiver who can troubleshoot
acute VAD alarms or complications and initiate an appropriate response always accompanies a pediatric patient.
Considerations should be made for the teenage VAD population who can gradually be trained to be more independent
in certain settings such as school. Simulation scenarios
have been developed to ensure the child and family are
comfortable prior to discharge and ongoing education
should be offered at designated times post discharge.
Outpatient Team: The VAD coordinator often serves as
a key point of contact. Unlike adult VAD programs, the
low center volumes lead to a decrease in local experts making it even more important to have a team member on call
to troubleshoot any acute issues. Outpatient surveillance
should routinely include monitoring anticoagulation and
markers of hemolysis; assessment of blood pressure;
inspection of driveline and equipment; and periodic echocardiograms for optimization of VAD settings.
Readmission: Pedimacs data as well as several small
series have shown that a majority of discharged VAD
patients are readmitted for reasons such as driveline or other
infections, anticoagulation management, suspected pump
thrombosis, and device malfunction or alarm.10,140,206

Preparing for transplantation
Sensitization while on a VAD: The development of antiHLA antibody after VAD has been reported in adult and
pediatric patients.209-222,223-225 While it is clear that patients
on VAD support have a transient increase in anti-HLA antibodies it remains unclear how VAD-related sensitization
impacts waiting list and transplant outcomes.223,224,226,224,227

However, despite higher sensitization in VAD patients, the
post-transplant outcomes for pediatric VAD patients are
equivalent to non-VAD patients.
Rehabilitation after VAD: A prolonged time for VAD
recovery and cardiac rehabilitation (CR) before listing for
HT has led to improved outcomes in some studies.228,229
CR is safe and effective after heart surgery, including
LVAD placement, in both children and adults.89,230-234 A
structured, multidisciplinary approach improves functional
capacity as measured by peak V02 and 6-minute walk
distance,231,234 peak heart rate with exercise,231 and
patient-reported QoL.230,231,234
Physical and occupational therapy should start early in
the ICU with achievement of hemodynamic and respiratory
stabilization.232 Range of motion exercises can be performed safely in the first few post-operative days with progression to sitting in a chair, standing, and walking.232
Patients should be encouraged to leave the acute care floor
and travel to the rehabilitation gym with VAD-trained staff
at the discretion of the VAD team. Early understanding of
specific debilities and attainable goals is necessary for creating an effective personalized rehabilitation prescription.
While frequency and duration vary, a common program
structure consists of 2-3 therapy sessions per week for 8-12
weeks.231,235 Goals of therapy include improvement of
functional capacity, return to age-appropriate activities of
daily living, and increased patient and parent-reported QoL.
Attention is also given to nutritional education, regular athome exercise, and psychosocial recovery. Despite the clear
benefits, CR attendance rates are low due to session frequency and distance from home.231 This reality has led to
the discussion of home-based therapy, where patients demonstrate competency with therapies at a rehab center before
finishing the remainder of CR at home. Home-based rehabilitation is an attractive option for VAD patients due to a
paucity of pediatric rehabilitation sites outside of the
implanting center.
Listing for transplant after VAD: An evolving area of
practice is the timing of listing for HT after VAD placement. The classical approach is to activate a patient on the
transplant list simultaneously with VAD placement to
reduce exposure to potential VAD complications that could
alter transplant candidacy. Lower adverse event rates seen
with CF-VADs have led some centers to optimize postVAD recovery prior to activation on the HT waiting list
and may be associated with better HT outcomes.228 Consideration may be given to delaying listing for transplant to
allow for rehabilitation, this is especially true after implantation of a durable CF LVAD. Should such a paradigm be
utilized, it is imperative to maximize physical, nutritional,
and psychological healing and CR during the recovery
interval. This recovery period also provides time for reverse
cardiac remodeling in which myocardial function may
improve, allowing VAD explantation in selective cases.236
At present, there is insufficient data for which wait list strategy optimizes patient outcomes. However, it is clear that
pediatric patients with intracorporeal CF VADs are being
supported for longer periods of time with 20% being supported greater than a year.
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Figure 2
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Discharge journey map from ACTION network (www.actionlearningnetwork.org) for patients on CF VADs.

Optimizing nutrition to improve post-transplant outcomes: Children with HF are often underweight as a result
of poor appetite, increased metabolic demands of the failing
heart, neurohormonal activation from heart failure, and
poor gastrointestinal perfusion. VAD support provides a
window for optimization of nutritional status prior to HT.
BMI less than the 5th percentile at the time of HT is an
independent predictor of decreased graft survival,237 though
that finding is not universal.238 A recent OPTN registry
study demonstrated that BMI > 95% or <1% were

independent risk factors for waitlist mortality in children
with cardiomyopathy, but BMI did not influence post-transplant survival.239 Nutritional status stratified by the percentage of ideal body weight at listing or at HT in children aged
< 2 years was associated with the increase in waitlist mortality, but not associated with post-transplant outcomes
(mortality rate, the incidences of infection, stroke or rejection before hospital discharge).240 Children less than 1 year
of age with hypoalbuminemia (< 2.0 g/dL) have worse
post-transplant survival.241 VAD utilization in children
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with advanced HF allows for improvement of hemodynamics, symptoms, and nutrition prior to transplant.242 Children
on VAD (EXCOR or HVAD) have been shown to have
greater improvement in nutritional status while awaiting
transplant than non-VAD supported candidates.243
VAD explant for transplantation: Each VAD patient
should have a peri-operative plan established at the time of
transplant listing. LVAD patients are at increased risk of
post-transplant vasoplegia and consideration should be
given to holding vasodilator medications such as ACE
inhibitors or ARNIs.244,245 Anticoagulation management
should aim to reverse anticoagulation prior to skin incision
when possible.

Post-transplant survival after VAD
Children supported with the EXCOR had equivalent 1- and
5-year post-transplant survival, infection rates and rejection
rates when compared to children who did not receive VAD
support in CHD and non-CHD patients.246,247 A linkage
analysis of patients enrolled in Pedimacs and Pediatric
Heart Transplant Society (PHTS) demonstrated similar
post-transplant survival, freedom from infection, and freedom from rejection between VAD and non-VAD HT recipients.248 Morbidity related to end-organ function may also
be mitigated by VAD support. Lower eGFR at VAD
implantation and failure to normalize eGFR during the
VAD support period are risk factors for post-transplant
chronic kidney disease.27 Transplant center procedural volume does not appear to influence 1-year post-transplant survival among children BTT with VAD.249

Key Points
 Testing for anti-HLA sensitization should occur in
patients on VAD support listed for HT with the understanding that some antibodies may only be present transiently and has not seem to effect post-transplant
outcomes.
 Cardiac rehabilitation should begin early post-operatively and advance to a multidisciplinary approach with
the goal of whole-body rehabilitation for HT or explanation when possible.
 Nutritional status should be optimized for all patients
both before and after VAD implantation.

End of life care of the pediatric patient on VAD
As VAD outcomes have improved in pediatrics, the focus is
no longer upon survival. Children are expected to survive
their VAD support course and there has been a recent focus
on their QoL. This has been the case in adult VAD literature
as well, with an increasing number of centers assessing QoL
before, during, and after VAD support, using patient
reported outcome (PRO) tools.
Communication with patients/families about VAD care,
risks/benefits, and prognosis is critical. Although these conversations can be challenging, pediatric cardiologists

believe they should have primary responsibility for such
discussions and generally feel comfortable discussing goals
of care and code status with parents.250 Conversations of
this nature with children and adolescents are understandably more difficult, as such, these topics are broached much
less with organ failure patients themselves.251 Emerging literature suggests that many young people prefer to be
involved in decision making about their end of life (EOL)
care if seriously ill.252 Among a pilot sample of adolescents
with HF, 83%, indicated a preference to be involved in their
EOL decision making.253 In addition to cultural considerations, care teams regularly assess preferences regarding
communication and decision making about EOL care. Care
teams should establish time points for assessing and revisiting these preferences, such as pre-implant, emergence of
VAD complication, and upon discharge. Honest conversations that occur throughout the pediatric VAD course will
decrease the likelihood for unexpected decision-making
during highly stressful times for families and care teams.252
Advance care planning allows one to specify healthcare
decisions if unable to speak for themselves. Across pediatric
illness and ACHD populations, a number of studies have
shown that many young people believe completing an
advance directive would be helpful.254-256 Adolescents with
HF report a preference for these conversations to be initiated
by a member of the healthcare team.253 Following assessment
of patient and family preferences, participation of all patients
in advance care planning should be considered.
The potential need for compassionate deactivation
should be discussed before a VAD is implanted. In the
event that EOL decision-making leads to a need for compassionate deactivation, there exist few resources for support. The scope of this challenge in pediatrics was initially
described by Hollander et al.,257 then a provider survey
illustrated a need for better education of clinicians in this
regard.258 Fortunately there now exist both adult259 and
pediatric260 checklists for compassionate deactivation,
which can improve on this process, as can the early involvement of pediatric palliative care services.
Bereavement support following the death of a child has
been recommended by both the American Academy of
Pediatrics (2013) and Institute of Medicine (2014).
Acknowledgement of the child’s death (e.g., condolence
letter, phone call) should be provided, along with psychoeducational materials about grief responses and available
support services through the hospital or community. Support groups, referral to individual counseling and annual
memorial services are helpful services to consider.261

Key Points
 Communication with parents and patients concerning
symptom management, decision-making, and advanced
care planning for known potential adverse events should
occur early and regularly.
 Program guidelines for when and how to proceed to compassionate deactivation are critical to support patients,
families and clinicians.
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Quality improvement and registry development
Pedimacs/INTERMACS/EUROMACS/IMACS/JMACS:
Relatively early in the evolution of mechanical circulatory
support, the Institute of Medicine recognized that the nature
and outcomes of MCS would be best understood through a
longitudinal registry.1 Aligned with that observation, in
2005 the NHLBI awarded a contract to the University of
Alabama to develop the INTERMACS registry for patients
in North America. Shortly after, INTERMACS began to
develop a pediatric component, Pedimacs, and was
launched in 2012.3 In 2018, INTERMACS and Pedimacs
became part of the STS National Database, joining the
Adult Cardiac Surgery Database, the General Thoracic Surgery Database and the Congenital Heart Surgery Database.
EUROMACS is the European registry for MCS that is
designed to improve the outcomes of patients on MCS. The
EUROMACS Committee of the European Association for
Cardio-Thoracic Surgery (EACTS) governs the registry,
which was launched in 2009 and became operational in
2012. EUROMACS is the only European-based durable
MCS registry for all devices with the CE Marking
implanted in children and adults.262 International Mechanically Assisted Circulatory Support (IMACS) collects data
from non-European countries but does not collect data on
pediatrics.263 JMACS collects data from hospitals in Japan
but does not collect data on children at this time.264
ACTION Network: ACTION is a multi-center learning
network whose initial aim was to minimize stroke rates
among pediatric patients requiring MCS. While clinical
data are being collected for more traditional hypothesisdriven research, quality improvement (QI) science will be
the primary modality through which ACTION is achieving
its goals. ACTION has employed the Institute for Healthcare Improvement (IHI) approach to QI.6,265
ACTION QI work to reduce stroke rates began with projects to improve anticoagulation, hemodynamics (i.e. blood
pressure control) and clinical team communication. Early
results have shown that interventions to standardize processes
for achieving anticoagulation to target goals, controlling
hypertension and checklists to improve team communication
have been successful across the consortium. Subsequent QI
initiatives are now in process and involve topics such as cardiac rehabilitation and hospital discharge, as well as another
focus on pre-VAD patient care to include optimizing pharmacologic management of decompensated HF to reduce in-hospital end-organ complications and death.
Harmonization by Doing (HBD): HBD is an innovative
concept that targets the limitations associated with low center
volumes. The pilot HBD initiative was launched in 2003.The
HBD program for global cardiovascular device innovation is
a collaboration of Japanese and US regulators, industry, and
academic clinicians, working to improve device investigation
by “sharing lessons learned from these experiences”. One of
the HBD working groups is a “study on post-market registry”, encompassing real-world evidence.12
Clinical Trials: Thus far, the only pediatric VAD device
completing a clinical trial has been the Berlin EXCOR
although the 50 cc TAH trial did include pediatrics and the

725

device has been approved for children that are the appropriate size.8,9 However, there is an ongoing trial (PumpKIN
Trial) that is sponsored by NIH on a small CF axial flow
pump (Jarvik Heart) for children.55
There are many limitations to device trials in pediatrics,
including patient volume and heterogeneity of population.
An additional limitation is understanding the relevance to
real-world practice. Although clinical trials are the gold
standard to develop scientific evidence regarding safety and
efficacy of a treatment, the limitations of clinical trials, in
pediatrics, have encouraged regulatory bodies and clinical
researchers to explore more diverse, real-world research
settings. The advancements in electronic health records,
clinical registries and technology integrated health systems
have enabled access to data that were not previously accessible and have offered possible sources for “real-world
evidence”.11 For the field of pediatric VAD, there is an
important role for real-world evidence, particularly in modifying or expanding device labeling. In addition to its QI
limb, the ACTION network also provides a prospectively
collected, adjudicated clinical registry as a source for realworld evidence for pediatric MCS devices.265
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